The FDA has classified as Class II an ongoing recall by Lupin Pharmaceuticals of clobetasol propionate cream USP 0.05% in 60 g tubes, for failing content uniformity specifications.
Content uniformity is the test that confirms the active drug is evenly distributed through the product. Failing it means the amount of clobetasol delivered in a given application may be higher or lower than the label states, and may vary within the tube. Class II is the middle category: the FDA uses it where a defect may cause temporary or medically reversible harm, and where serious harm is unlikely. For a superpotent topical steroid the plausible consequences run both ways — under-treatment of a resistant plaque read as treatment failure, or over-delivery with the atrophy, striae and telangiectasia that follow.
The practical action is dispensary-level: identify affected lots against the FDA notice and quarantine them. Clinically, it is a reminder to think about the product before escalating potency. A patient whose disease has stopped responding to a preparation they were previously doing well on deserves the question of whether the tube changed, alongside adherence and quantity. This is a US recall of specific manufactured lots; Lupin manufactures in India but the recall as posted concerns product for the US market, and no CDSCO action has been reported.
- Check dispensary stock against the recalled lot numbers and quarantine what matches
- Class II means possible temporary or reversible harm, not a serious safety alert
- Consider a product or lot change when a previously well-controlled patient stops responding
- Review any patient with unexpected atrophy or striae on a supposedly standard regimen
- This is a recall of US-market lots; no CDSCO action has been reported for Indian supply
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free